Please login to the form below

baricitinib

This page shows the latest baricitinib news and features for those working in and with pharma, biotech and healthcare.

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

This includes remdesivir, and Gilead is planning combination studies of the antiviral drug when taken alongside Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.

Latest news

Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

with Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

and rheumatoid arthritis drug Olumiant (baricitinib).
Incyte’s JAK inhibitor cream clears second eczema trial

The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

tofacitinib) and Eli Lilly’s Olumiant (baricitinib).

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Latest Intelligence

AI: the smart money is on the smart thinking

Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.
Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story: How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA: Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?: While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...